Barely Significant
← all excerpts

CCR7 alterations associated with inferior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.

Hematol Oncol · 2022 · PMC10087024 · PMID 36043457

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

highly significantp < 0.001actually significant
In contrast, the difference in median survival from the first dose of antibody of patients with or without TP53 alterations was highly significant, at 0.7 versus 5.1 years, respectively ( p < 0.001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.